Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myelin Peptide-loaded tolDC in Multiple Sclerosis
2024-512891-37-00Phase 2Completed
- Sponsor
- Antwerp University Hospital
- Start
- Nov 2024
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 2
01
Overview
Phase 2, randomised trial in multiple sclerosis (MS) comparing Control arm – standard-of-care or no DMT with Intervention arm – tolDC (2 arms). Primary endpoint: Number of new and enlarging T2 lesions on MRI. Started Nov 2024; status: completed.
02
Drugs
myelin peptide-loaded tolerogenic dendritic cells
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-512891-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512891-37-00.